Cervical Cancer
Expanding HPV vaccination to age 45 years not as cost-effective as current strategy
Cancer incidence not always the best measure of cancer trends

Cancer incidence rates represent one key measure of progress in the fight against cancer, but they are not the only consideration. According to a special report published in The New England Journal of Medicine, concordance between incidence and mortality rates provides a more complete picture of cancer burden.
Reduce stigma, improve education to increase cancer treatment among patients with HIV
Nivolumab-ipilimumab combination benefits women with advanced cervical cancer

BARCELONA, Spain — Nivolumab in combination with ipilimumab conferred clinical benefit for women with recurrent or metastatic cervical cancer regardless of PD-L1 status, according to results of the randomized phase 1b/phase 2 CheckMate 358 study presented at European Society for Medical Oncology Congress.